NCT00184080View on ClinicalTrials.gov

Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

April 30, 2006

Study Completion Date

April 30, 2006

Conditions
Non-Hodgkin's Lymphoma
Interventions
DRUG

Elsamitrusin

Trial Locations (1)

90032

USC/Norris Comprehensive Cancer Center, Los Angeles

All Listed Sponsors
collaborator

Spectrum Pharmaceuticals, Inc

INDUSTRY

lead

University of Southern California

OTHER

NCT00184080 - Elsamitrucin (SPP 28090) in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter